Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Avalo Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 32 | 26 | −6 |
| Shares | 9.13M | 2.43M | −6.70M (−73.4%) |
| Value | $16.0M | $862.7K | −$15.1M (−94.6%) |
New holders (4)
Institutions that held Avalo Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 32,593 | $12.0K | 0.00% |
| Two Sigma Securities, LLC | 20,532 | $7.29K | 0.00% |
| Commonwealth Equity Services, LLC | 10,762 | $4.00K | 0.00% |
| HRT Financial LP | 13,106 | $4.00K | 0.00% |
Sold out (10)
Institutions that held Avalo Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Armistice Capital, LLC | 4,415,000 | $7.73M |
| Point72 Asset Management, L.P. | 1,100,737 | $1.93M |
| Great Point Partners LLC | 474,639 | $830.6K |
| Alyeska Investment Group, L.P. | 400,000 | $700.0K |
| Braidwell LP | 247,254 | $432.7K |
| Maven Securities LTD | 92,937 | $162.6K |
| Monashee Investment Management LLC | 60,000 | $105.0K |
| Goldman Sachs Group Inc | 32,261 | $56.5K |
| TCI Wealth Advisors, Inc. | 251 | $440 |
| The PNC Financial Services Group, Inc. | 6 | $10 |